POMPANO BEACH, FL / ACCESSWIRE / October 17, 2023 / BioStem Technologies Inc. (OTC PINK:BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that it will highlight the advantages of its Vendaje® and AmnioWrap2TM portfolios to help patients with difficult to heal chronic wounds at the 2023 Symposium on Advanced Wound Care (SAWC) Fall Conference held November 3rd - 5th in Las Vegas, Nevada.
"We are thrilled to attend the 2023 SAWC Fall Conference this year. This is the first year that we are exhibiting, and it is a great opportunity for us to spotlight our portfolio and scientifically demonstrate how using our BioREtain® process makes a differentiated product that not only better retains key factors such as extracellular matrix, growth factors and anti-inflammatory cytokines, but is effective to help stalled wounds such as Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs), to heal," said Jason Matuszewski, CEO of BioStem Technologies, Inc.
Attendees should visit the BioStem exhibit hall booth (#645) to learn more about the Vendaje and AmnioWrap2 product portfolios. BioStem representatives will be available to discuss product applications and benefits to fit the needs of hospitals, clinics and private practices.
The booth will be open during the following hours:
Friday, November 3 - 4:45-6:45 p.m.
Saturday, November 4 - 12:30-3:00 p.m.
Sunday, November 5 - 12:30-2:00 p.m. For more information, sign up @ www.biostemtechnologies.com/biostem-form
About VendajeⓇ and AmnioWrap2TM
Vendaje and AmnioWrap2 are placental-derived, minimally manipulated dehydrated tissue allografts that serve as a protective covering for soft tissue wounds. The product is comprised of extracellular matrix scaffolding which provides mechanical protection and functional support for cell migration, growth factors that help modulate proliferation and angiogenesis, and anti-inflammatory cytokines that inhibit inflammatory effects, all critical to aiding the body's natural healing cascade.
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and Linkedin.
Forward-Looking Statements:
Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate", "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company's products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company's fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStemTechnologies
Jason Matuszewki
jason@biostemtech.com
(414) 339-4768
SOURCE: BioStem Technologies, Inc.
via PRISM Mediawire, LLC
View source version on accesswire.com:
https://www.accesswire.com/793760/biostem-technologies-to-highlight-core-advanced-wound-care-portfolio-at-sawc-fall-2023-conference
